Working Group 3

AI/ML Use in PGx of Cardiovascular Medicine

wORKING GROUP 3

AI/ML Use in PGx of Cardiovascular Medicine

Working Group 3 focuses on leveraging artificial intelligence (AI) and machine learning (ML) to enhance pharmacogenomic applications in cardiovascular medicine. The group develops advanced computational approaches to support data-driven decision-making and improve the precision of therapy selection.

Dr Lemana Spahić

Bosnia and Herzegovina Medical and Biological Engineering Society

Key activities include the development of AI-based dosing algorithms, analysis of computational infrastructure across Europe, and creation of a centralized digital platform for pharmacogenomic data. This platform will enable secure data sharing, integration, and real-time access for researchers and clinicians.

WG3 also evaluates the technological requirements for integrating PGx into clinical systems, ensuring that healthcare providers have the necessary tools to implement personalized medicine effectively.